SCHEMBL3418282

SCHEMBL3418282

Nc1nc(-c2ccc(Br)s2)cs1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.63
ALDH1A1 P00352 8/20 0.63
HSD17B10 Q99714 7/20 0.63
NPC1 O15118 5/20 0.63
GFER P55789 1/20 0.63
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
ALOX15 P16050 1/20 0.55
ALOX12 P18054 1/20 0.55
CYP3A4 P08684 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
KDM4E B2RXH2 4/20 0.51
LMNA P02545 2/20 0.51
ABL1 P00519 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4160754 0.78 KDM4E (0.54) MAPTALDH1A1HSD17B10NPC1GFER
SCHEMBL21484904 0.78 ALDH1A1 (1.00) MAPTALDH1A1HSD17B10NPC1GFER
SCHEMBL2763422 0.76 ALDH1A1 (0.63) MAPTALDH1A1HSD17B10NPC1GFER
SCHEMBL29152951 0.74 KDM4E (0.66) MAPTALDH1A1HSD17B10NPC1GFER
SCHEMBL29225378 0.74 NPC1 (0.47) MAPTALDH1A1HSD17B10NPC1GFER
SCHEMBL18724191 0.73 MAPT (0.53) MAPTALDH1A1HSD17B10NPC1GFER
SCHEMBL10519613 0.73 ALDH1A1 (0.59) MAPTALDH1A1HSD17B10NPC1GFER
SCHEMBL17336663 0.73 KDM4E (0.56) MAPTALDH1A1HSD17B10NPC1MEN1
SCHEMBL4422474 0.73 HDAC1 (0.57) MAPTALDH1A1HSD17B10NPC1GFER
SCHEMBL10719025 0.72 ALDH1A1 (0.61) MAPTALDH1A1HSD17B10NPC1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117486872-A Mechanical ball milling synthesis method of aminothiazole compound 浙江工业大学 2024-02-02 CN disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
US-9708279-B2 2-acylaminothiazoles for the treatment of cancer UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) 2017-07-18 US disclosed
EP-3016948-B1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) 2017-05-10 EP disclosed
EP-3016948-B1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) 2017-05-10 EP disclosed
US-20160257658-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) 2016-09-08 US disclosed
US-20160257658-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) 2016-09-08 US disclosed
US-20160257658-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) 2016-09-08 US disclosed
EP-3016948-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER Università Degli Studi Di Milano - Bicocca (IT) 2016-05-11 EP disclosed
WO-2015001024-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2015-01-08 WO disclosed
WO-2015001024-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2015-01-08 WO disclosed
WO-2010065383-A1 CALCILYTIC COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MAPT 706/4885ALDH1A1 2267/4885HSD17B10 2790/4885
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 MAPT 1351/4885ALDH1A1 1635/4885HSD17B10 3064/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MAPT 706/4885ALDH1A1 2267/4885HSD17B10 2790/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 MAPT 1351/4885ALDH1A1 1635/4885HSD17B10 3064/4885
US-20160257658-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER ALK, ERBB2, ABL1 MAPT 2591/4885ALDH1A1 367/4885HSD17B10 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.